UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of March 2025
Commission File Number: 001-41621
RADIOPHARM THERANOSTICS LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South,
Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes ☐ No
☒
If “Yes” is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82-
RADIOPHARM THERANOSTICS LIMITED
EXPLANATORY NOTE
Radiopharm Theranostics Limited (the “Company”)
published one announcement (the “Public Notice”) to the Australian Securities Exchange on March 7, 2025 titled:
| - | “Update - Notification regarding unquoted securities -
RAD” |
A copy of the Public Notice is attached as an exhibit to this report
on Form 6-K.
This report on Form 6-K (including the exhibit
hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.
EXHIBITS
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
RADIOPHARM THERANOSTICS LIMITED |
|
|
|
Date: March 7, 2025 |
By: |
/s/ Phillip Hains |
|
|
Phillip Hains |
|
|
Company Secretary |
3
Exhibit 99.1
 |
Appendix 3G - Notification of issue, conversion or payment up of unquoted
equity securities |
Entity name
RADIOPHARM THERANOSTICS LIMITED
Announcement Type
Update to previous announcement
Date of this announcement
Friday March 07, 2025
Reason for the update
|
Correction to Q5.1a, equities issued under LR 7.2 Exception 13 |
Refer to next page for full details of the announcement
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | 1 / 6 |
 |
Appendix 3G - Notification of issue, conversion or payment up of unquoted
equity securities |
Part 1 - Entity and announcement details |
|
|
|
1.1
Name of entity
RADIOPHARM THERANOSTICS LIMITED
We (the entity named above) give notice of the issue, conversion
or payment up of the following unquoted +securities.
|
1.2 Registered number type |
Registration number |
|
ACN |
647877889 |
1.3
ASX issuer code
RAD
1.4
The announcement is
Update/amendment to previous announcement
1.4a Reason
for update to a previous announcement
|
Correction to Q5.1a, equities issued under LR 7.2 Exception 13 |
1.4
b Date of previous announcement to this update
7/3/2025
1.5
Date of this announcement
7/3/2025
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | 2 / 6 |
 |
Appendix 3G - Notification of issue, conversion or payment up of unquoted
equity securities |
2.1
The +securities the subject of this notification are:
+Other securities issued under an +employee incentive scheme
that are not intended to be quoted on ASX
2.2a This notification is
given in relation to an issue of +securities in a class which is not quoted on ASX and which:
has an existing ASX security code (“existing class”)
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | 3 / 6 |
 |
Appendix 3G - Notification of issue, conversion or payment up of unquoted
equity securities |
Part 3B - number and type of +securities
the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B
ASX +security code and description
RADAN : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES
Date the +securities the subject of this notification
were issued
6/3/2025
Will these +securities rank equally in all respects
from their issue date with the existing issued +securities in that class
Yes
Were any of the +securities issued to +key management
personnel (KMP) or an +associate?
No
Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme
or a summary of the terms
|
Notice of 2024 AGM
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02871492-2A1557838
|
Any other information the entity wishes to provide
about the +securities the subject of this notification
Issue details
Number of +securities
400,000
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | 4 / 6 |
 |
Appendix 3G - Notification of issue, conversion or payment up of unquoted
equity securities |
Part 4 - +Securities on issue |
|
|
|
Following the issue, conversion or payment up of
the +securities the subject of this notification, the +securities of the entity will comprise:
The figures in parts
4.1 and 4.2 below are automatically generated and may not reflect the entity’s current issued capital if other Appendix 2A, Appendix
3G or Appendix 3H forms are currently with ASX for processing.
4.1
Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)
| |
Total
number of | |
ASX +security code and description | |
+securities
on issue | |
RADO : OPTION EXPIRING 30-NOV-2026 | |
| 79,352,040 | |
RAD : ORDINARY FULLY PAID | |
| 2,333,980,142 | |
RADOA : OPTION EXPIRING 24-AUG-2026 | |
| 818,890,534 | |
4.2
Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)
ASX +security code and description | |
Total
number of
+securities
on issue | |
RADAK : OPTION EXPIRING 01-JUN-2027 EX $0.60 | |
| 1,666,500 | |
RADAE : OPTION EXPIRING 25-NOV-2025 RESTRICTED | |
| 5,700,006 | |
RADAN : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES | |
| 209,716,866 | |
RADAJ : OPTION EXPIRING 01-JUL-2027 EX $0.17 | |
| 13,137,976 | |
RADAF : OPTION EXPIRING 25-NOV-2026 RESTRICTED | |
| 8,666,678 | |
RADAG : OPTION EXPIRING 25-NOV-2026 EX $0.60 | |
| 5,066,672 | |
RADAH : OPTION EXPIRING 22-DEC-2025 EX $0.60 | |
| 400,000 | |
RADAI : OPTION EXPIRING 27-MAY-2027 EX $0.60 | |
| 740,000 | |
RADAP : OPTION EXPIRING 24-APR-2028 EX $0.09 | |
| 8,955,224 | |
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities | 5 / 6 |
 |
Appendix 3G - Notification of issue, conversion or payment up of unquoted
equity securities |
Part 5 - Other Listing Rule requirements |
|
|
|
5.1 Were the +securities issued
under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?
Yes
5.1a
Select the number of the applicable exception in Listing Rule 7.2
13
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities |
6 / 6 |
Radiopharm Theranostics (NASDAQ:RADX)
Historical Stock Chart
From Feb 2025 to Mar 2025
Radiopharm Theranostics (NASDAQ:RADX)
Historical Stock Chart
From Mar 2024 to Mar 2025